Background There is some controversy on the potential relationship between autoimmune processes and clinicopathological features as well as prognosis of differentiated thyroid cancer (DTC), and the evidence is limited by its largely retrospective nature. We examined the relationship between the presence of autoimmune thyroiditis and 1-year thyroid cancer treatment outcomes in a large, multi-center study, using prospectively collected data. Methods We included data from consecutive DTC patients enrolled in the Italian Thyroid Cancer observatory (ITCO) database (NCT04031339). We divided the groups according to the presence (AT) or absence (noAT) of associated autoimmune thyroiditis. We used propensity score matching to compare the clinical features and outcomes between the 2 groups at 1-year follow-up. Results We included data from 4233 DTC patients, including 3172 (75%) females. The American Thyroid Association (ATA) risk levels were as follows: 51% (2160/4233) low risk, 41.3% (1750/4233) intermediate risk, and 7.6% (323/4233) high risk. There were 1552 patients (36.7%) who had autoimmune thyroiditis. Before propensity score matching, AT patients were significantly younger, and had a smaller and bilateral tumor (p<0.0001). Patients with AT more frequently fell into the low and intermediate risk categories, while ATA high risk was more frequent among noAT patients (p=0.004). After propensity score matching, patients with AT more frequently showed evidence of disease (structural/biochemical incomplete response) versus excellent/indeterminate response, compared to patients without AT (7.3% versus 4.5%, p=0.001), with an OR of 1.86 (95% CI: 1.3-2.6, p=0.0001). However, when considering only structural persistence as the outcome, no statistically significant differences were observed between patients with or without AT (3.4% versus 2.7%, p=0.35). The elevated risk associated with ATA intermediate and high risk at diagnosis remained consistently statistically significant. Conclusions In this large prospective series, biochemical persistence was more frequent, at one-year follow-up, in AT patients. However, there was no significant association between the presence of AT and structural persistence of disease. These findings may be explained by the presence of a residual thyroid tissue.

A Prospective, Multicenter Study Examining the Relationship between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis / De Leo, Simone; D'Elia, Silvia; Grani, Giorgio; Dondi, Francesco; Bertagna, Francesco; Puxeddu, Efisio; Morelli, Silvia; Piovesan, Alessandro; Nervo, Alice; Zatelli, MARIA CHIARA; Gagliardi, Irene; Teresa Sam(`(a)), Maria; Aimaretti, Gianluca; Crocetti, Umberto; Massa, Michela; Deandrea, Maurilio; Retta, Francesca; Pagano, Loredana; Rossi, Mattia; Solaroli, Erica; Pezzullo, Luciano; Grazia Chiofalo, Maria; Pontecorvi, Alfredo; Pio Lombardi, Celestino; Antonelli, Alessandro; Patrizio, Armando; Messuti, Ilaria; Magri, Flavia; Spiazzi, Giovanna; Ceresini, Graziano; Bruno, Rocco; Sparano, Clotilde; Centanni, Marco; Crescenzi, Anna; Tallini, Giovanni; Marotta, Vincenzo; Madeo, Bruno; Mian, Caterina; Filetti, Sebastiano; Durante, Cosimo; Fugazzola, Laura. - In: THYROID. - ISSN 1050-7256. - (2023). [10.1089/thy.2023.0052]

A Prospective, Multicenter Study Examining the Relationship between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis

Silvia D'Elia;Giorgio Grani;Maria Chiara Zatelli;Marco Centanni;Anna Crescenzi;Sebastiano Filetti;Cosimo Durante;
2023

Abstract

Background There is some controversy on the potential relationship between autoimmune processes and clinicopathological features as well as prognosis of differentiated thyroid cancer (DTC), and the evidence is limited by its largely retrospective nature. We examined the relationship between the presence of autoimmune thyroiditis and 1-year thyroid cancer treatment outcomes in a large, multi-center study, using prospectively collected data. Methods We included data from consecutive DTC patients enrolled in the Italian Thyroid Cancer observatory (ITCO) database (NCT04031339). We divided the groups according to the presence (AT) or absence (noAT) of associated autoimmune thyroiditis. We used propensity score matching to compare the clinical features and outcomes between the 2 groups at 1-year follow-up. Results We included data from 4233 DTC patients, including 3172 (75%) females. The American Thyroid Association (ATA) risk levels were as follows: 51% (2160/4233) low risk, 41.3% (1750/4233) intermediate risk, and 7.6% (323/4233) high risk. There were 1552 patients (36.7%) who had autoimmune thyroiditis. Before propensity score matching, AT patients were significantly younger, and had a smaller and bilateral tumor (p<0.0001). Patients with AT more frequently fell into the low and intermediate risk categories, while ATA high risk was more frequent among noAT patients (p=0.004). After propensity score matching, patients with AT more frequently showed evidence of disease (structural/biochemical incomplete response) versus excellent/indeterminate response, compared to patients without AT (7.3% versus 4.5%, p=0.001), with an OR of 1.86 (95% CI: 1.3-2.6, p=0.0001). However, when considering only structural persistence as the outcome, no statistically significant differences were observed between patients with or without AT (3.4% versus 2.7%, p=0.35). The elevated risk associated with ATA intermediate and high risk at diagnosis remained consistently statistically significant. Conclusions In this large prospective series, biochemical persistence was more frequent, at one-year follow-up, in AT patients. However, there was no significant association between the presence of AT and structural persistence of disease. These findings may be explained by the presence of a residual thyroid tissue.
2023
thyroiditis; prospective; thyroid cancer; outcome, radioiodine
01 Pubblicazione su rivista::01a Articolo in rivista
A Prospective, Multicenter Study Examining the Relationship between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis / De Leo, Simone; D'Elia, Silvia; Grani, Giorgio; Dondi, Francesco; Bertagna, Francesco; Puxeddu, Efisio; Morelli, Silvia; Piovesan, Alessandro; Nervo, Alice; Zatelli, MARIA CHIARA; Gagliardi, Irene; Teresa Sam(`(a)), Maria; Aimaretti, Gianluca; Crocetti, Umberto; Massa, Michela; Deandrea, Maurilio; Retta, Francesca; Pagano, Loredana; Rossi, Mattia; Solaroli, Erica; Pezzullo, Luciano; Grazia Chiofalo, Maria; Pontecorvi, Alfredo; Pio Lombardi, Celestino; Antonelli, Alessandro; Patrizio, Armando; Messuti, Ilaria; Magri, Flavia; Spiazzi, Giovanna; Ceresini, Graziano; Bruno, Rocco; Sparano, Clotilde; Centanni, Marco; Crescenzi, Anna; Tallini, Giovanni; Marotta, Vincenzo; Madeo, Bruno; Mian, Caterina; Filetti, Sebastiano; Durante, Cosimo; Fugazzola, Laura. - In: THYROID. - ISSN 1050-7256. - (2023). [10.1089/thy.2023.0052]
File allegati a questo prodotto
File Dimensione Formato  
thy.2023.0052.pdf

accesso aperto

Note: De Leo_A Prospective, Multicenter Study_2023
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1 MB
Formato Adobe PDF
1 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1688850
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact